-
Sanofi-Aventis U.S. LLC, et al. v. Sandoz Inc. DC CAFC
- 1:20-cv-00804
- D. Del.
- Judge: Richard G. Andrews
- Filed: 06/12/2020
- Closed: 07/05/2023
- Latest Docket Entry: 10/18/2023
- PACER
- Docket updated daily
2
Plaintiffs
20
Defendants
4
Accused
Products
3
Patents-in-Suit
1,119
Days in
Litigation
-
Sanofi-Aventis U.S. LLC, et al. v. Sandoz Inc. DC CAFC
- 1:20-cv-00804
- D. Del.
- Judge: Richard G. Andrews
- Filed: 06/12/2020
- Closed: 07/05/2023
- Latest Docket Entry: 10/18/2023
- PACER
- Docket updated daily
Causes of Action
Infringement
Declaratory Judgment
Patent Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A method of increasing survival comprising administering to a patient in need thereof a dose of 20 to 25 mg/m2 of cabazitaxel, or a hydrate or solvate thereof, in combination with an H2 antagonist, wherein the H2 antagonist is administered to the
view more
|
Valid
Entry 373 |
| 2 |
The method of claim 1, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 20 mg/m2.
|
Valid
Entry 373 |
| 4 |
The method of claim 1, where the H2 antagonist is administered at least 30 minutes prior to administering the dose of cabazitaxel.
|
Valid
Entry 373 |
| 5 |
The method of claim 4, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 20 mg/m2.
|
Valid
Entry 373 |
-
Infringement
Sandoz Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic Cabazitaxel Injection, 10 mg/mLGeneric Cabazitaxel Injection, 45 mg/4.5 mLGeneric Cabazitaxel Injection, 60 mg/1.5 mLGeneric Cabazitaxel Injection, 60 mg/6 mL | US 10,716,777 B2 |
1, 2, 4, 5
|
Infringement
Entry 373
|
